Participant flow

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors · Source last updated 2025-10-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Adult participants (≥ 18 years) were administered Tovorafenib 600 mg orally (PO) once weekly (QW).

   id

   FG000

   title

   Melanoma Cohort

2. description

   Adult participants (≥ 18 years) were administered Tovorafenib 600 mg PO QW.

   id

   FG001

   title

   Tissue Agnostic Cohort

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         4

      2. group Id

         FG001

         num Subjects

         6

      type

      Death

   2. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         1

      type

      Withdrawal by Subject

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         8

      2. group Id

         FG001

         num Subjects

         15

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         4

      2. group Id

         FG001

         num Subjects

         8

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         4

      2. group Id

         FG001

         num Subjects

         7

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

A total of 31 participants consented, of which 23 participants were enrolled into Melanoma and Tissue Agnostic cohorts. Remaining 8 participants were screen failures.

recruitment Details

This study was conducted at 11 centers that enrolled participants in 6 countries.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice